References
- Osher E, Weisinger G, Limor R, et al. The 5-lipoxygenase system in the vasculature: Emerging role in health and disease. Mol Cell Endocrinol 2006; 252: 201–206
- Zhou Y, Wei E, Fang S, et al. Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci 2006; 79: 1645–1656
- Chu L, Fang S, Zhou Y, et al. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin 2007; 28: 763–772
- Ohtsuki T, Matsumoto M, Hayashi Y, et al. Reperfusion induces 5-lipoxygenase translocation and leukotriene C4 production in ischemic brain. Am] Physiol 1995; 268: 1249–1257
- St-Pierre Y, Couillard J, van Themsche C. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin Ther Targets 2004; 8: 473–489
- Yong VVV, Krekoski CA, Forsyth PA, et al. Matrix metalloprotei-nases and diseases of the CNS. Trends Neurosci 1998; 21: 75–80
- Gasche Y, Fujimura M, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood—brain barrier dysfunc-tion. J Cereb Blood Flow Metab 1999; 19: 1020–1028
- Fujimura M, Gasche Y, Morita-Fujimura Y, et al. Early appearance of activated matrix metalloproteinase-9 and blood—brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842: 92–100
- Carter GW, Young PR, Albert DH, et al. 5-lipoxygenase inhibitory activity of zileuton. I Pharmacol Exp Ther 1991; 256: 929–937
- Patel NSA, Cuzzocrea S, Chatterjee PK, et al. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol 2004; 66: 220–227
- Ye YN, Wu WKK, Shin VY, et al. A mechanistic study of colon cancer growth promoted by cigarette smoke extract. Fur I Pharmacol 2005; 519: 52–57
- Cipollone F, Mezzetti A, Fazia ML, et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 2005; 25: 1665–1670
- Li Y, Xua Z, Ford GD, et al. Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia. Brain Res 2007; 1184: 277–283
- Lin TN, He YY, Wu G, et al. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke 1993; 24: 117-121
- Asahi M, Asahi K, Jung JC, et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94. I Cereb Blood Flow Metab 2000; 20: 1681–1689
- Lazarus SC, Lee T, Kemp JP, et al. Safety and clinical efficacy of zileuton in patients with chronic asthma. Am] Manag Care 1998; 4: 841–848
- Baskaya MK, Hu Y, Donaldson D, et al. Protective effect of the 5-lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia. ] Neurosurg 1996; 85: 112–116
- Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood—brain barrier opening after reperfusion in rat brain. Stroke 1998; 29: 2189–2195
- Jatana M, Gin i S, Ansari MA, et al. Inhibition of NF-KB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. J Neuroinflammation 2006; 3: 12
- Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29: 1020–1030
- Collin M, Rossi A, Cuzzocrea S, et al. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J Leukoc Biol 2004; 76: 961–970
- Chen X, Wang S, Wu N, et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004; 10: 6703–6709
- Xue M, Yong VW. Matrix metalloproteinases in intracerebral hemorrhage. Neurol Res 2008; 30: 775–782
- Yong VW. The potential use of MMP inhibitors to treat CNS diseases. Exp Opin Investig Drugs 1999; 8: 255–268
- Asahi M, Sumii T, Fini ME, et al. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 2001; 12: 3003–3007